Article
Allergy
Diego Alvarado, Marcus Maurer, Richard Gedrich, Scott B. Seibel, Michael B. Murphy, Linda Crew, Joel Goldstein, Andrea Crocker, Laura A. Vitale, Pamela A. Morani, Lawrence J. Thomas, Thomas R. Hawthorne, Tibor Keler, Diane Young, Elizabeth Crowley, Martin Kankam, Margo Heath-Chiozzi
Summary: In this study, CDX-0159, an anti-KIT monoclonal antibody, was found to effectively suppress MCs and showed safety and long antibody exposure in healthy volunteers. Importantly, CDX-0159 also demonstrated dose-dependent profound suppression of plasma tryptase, indicating systemic MC suppression or ablation.
Article
Cell Biology
Kwang-Hyeok Kim, Jin-Ock Kim, Sang Gyu Park
Summary: In this study, a novel therapeutic agent for mast cell diseases was developed - 2G4 antibody, which was shown to effectively inhibit mast cell proliferation, migration, degranulation, and secretion of pro-inflammatory cytokines in LAD2 cells. These findings suggest that 2G4 antibody has potential as a promising treatment option for mast cell diseases.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Terence L. Kirley, Andrew B. Norman, Kenneth D. Greis
Summary: Researchers have developed a high-affinity anti-cocaine antibody for the treatment of cocaine use disorders. They found that oxidation affects the binding of the antibody to cocaine, but excess methionine can protect the antibody from oxidation. Additionally, oxidation leads to a decrease in tryptophan fluorescence and the presence of oxidized forms of tryptophan.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2022)
Article
Microbiology
Nikola Kurbatfinski, Steven D. Goodman, Lauren O. Bakaletz
Summary: New strategies are needed to treat diseases in which biofilms contribute significantly to pathogenesis. Dispersing or disrupting biofilms renders bacteria released from biofilm residence highly sensitive to killing by specific antibiotics. A humanized monoclonal antibody targeting DNABII protein successfully disrupts biofilms formed by respiratory tract pathogens and enhances antibiotic-mediated killing of released bacteria.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Biochemistry & Molecular Biology
Dan-dan Zhou, Li-ping Sun, Qun Yu, Xiao-tian Zhai, Lan-wen Zhang, Rui-juan Gao, Yong-su Zhen, Rong Wang, Qing-fang Miao
Summary: The novel anti-Trop2 antibody IMB1636 exhibited high affinity and specificity in binding antigens, cancer cells, and human tumor tissues. It induced endocytosis and targeted delivery to the tumor site. The humanized antibody hIMB1636 showed potential in inhibiting cancer cell proliferation and migration, and inducing ADCC effects. Moreover, hIMB1636 significantly inhibited tumor growth in vivo.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Immunology
Lei Chen, Jiansheng Lu, Junjie Yue, Rong Wang, Peng Du, Yunzhou Yu, Jiazheng Guo, Xi Wang, Yujia Jiang, Kexuan Cheng, Zhixin Yang, Tao Zheng
Summary: A humanized monoclonal antibody 9-8-h2, derived from mice immunization, showed potent neutralization activity against HAdV55. It recognized a conformational neutralization epitope and had favorable physicochemical properties. It could be a promising molecule for the prevention and treatment of HAdV55.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Veterinary Sciences
Davide De Biase, Francesco Prisco, Giuseppe Piegari, Arianna Ilsami, Ilaria D'Aquino, Valeria Baldassarre, Federica Zito Marino, Renato Franco, Serenella Papparella, Orlando Paciello
Summary: RNA expression can be used as an indicator of genetic changes in cells, with RNAScope showing promise as a method for evaluating c-KIT mRNA levels in canine mast cell tumors. The study found significant correlations between c-KIT mRNA expression and histological grade, highlighting the potential for c-KIT mRNA as a prognostic marker in canine MCTs.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Article
Biochemistry & Molecular Biology
Kwang-Hyeok Kim, Jin-Ock Kim, Jeong-Yang Park, Min-Duk Seo, Sang Gyu Park
Summary: Lung cancer is a major cause of cancer-related deaths, with small cell lung cancer (SCLC) accounting for a significant portion. Overexpression of c-Kit is a characteristic of SCLC. This study found that the antibody-drug conjugate 4C9-DM1 shows potential as a therapeutic agent for SCLC, as it efficiently induces apoptosis and inhibits tumor growth. Combination treatment with other drugs further enhances its anti-tumor effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Ayana Iijima, Kazumasa Kanemaru, Yaqiu Wang, Tsukasa Nabekura, Yoshiyuki Nakamura, Yasuhiro Fujisawa, Daiki Mori, Masaki Ohmuraya, Sho Yamasaki, Satoko Tahara-Hanaoka, Akira Shibuya
Summary: Mast cells (MCs) have specific expression of Clec12b in the skin of mice, but not in other tissues or immune cell types. A newly generated monoclonal antibody was able to recognize Clec12b and flow cytometry analysis confirmed its expression only on skin MCs in mice, as well as in humans. This suggests that Clec12b plays a significant role in regulating MCs activation in the skin.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Food Science & Technology
Zhi Li, Hua Xu, Bo Ma, Li Luo, Lei Guo, Pingping Zhang, Yong Zhao, Lili Wang, Jianwei Xie
Summary: Abrin is a highly toxic protein isolated from Abrus precatorious seeds, which has the potential to be used as a bioterrorism agent. Currently, there are no antidotes available for abrin poisoning, and neutralizing antibodies are the most effective therapy. In this study, a high-affinity neutralizing monoclonal antibody 10D8 was prepared and found to have a strong protective effect against abrin-induced toxicity.
Review
Medicine, General & Internal
Guy G. Brusselle, Gerard H. Koppelman
Summary: Biologic therapies may be necessary to reduce the disease burden and risks for severe asthma patients. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Susan Pederson, David M. Biondi, Brent Allan, Roger Cady, Barbara Schaeffler, Brian Baker, John Latham
Summary: Across five clinical trials, the immunogenicity of eptinezumab was characterized by low titer and transient ADA and NAb responses, with no clinically meaningful impact on efficacy and safety profiles. The onset of detectable ADA occurred at week 8, peaked at week 24, and declined steadily thereafter, regardless of eptinezumab dose level or number of doses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Madoka Nagata, Jinhee Lee, Taro Saito, Kazunori Ikebukuro, Koji Sode
Summary: This study presents an anti-idiotype aptamer-based electrochemical sensor for measuring the therapeutic antibody bevacizumab. The sensor was able to detect the target antibody within 30 minutes using a modified anti-idiotype bivalent aptamer. The sensor achieved detection of bevacizumab in the range of 1-100 nM without the need for free redox probes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Veterinary Sciences
Michael Willmann, Vilma Yuzbasiyan-Gurkan, Laura Marconato, Mauro Dacasto, Emir Hadzijusufovic, Olivier Hermine, Irina Sadovnik, Susanne Gamperl, Mathias Schneeweiss-Gleixner, Karoline V. Gleixner, Thomas Boehm, Barbara Peter, Gregor Eisenwort, Richard Moriggl, Zhixiong Li, Mohamad Jawhar, Karl Sotlar, Erika Jensen-Jarolim, Veronika Sexl, Hans-Peter Horny, Stephen J. Galli, Michel Arock, David M. Vail, Matti Kiupel, Peter Valent
Summary: Mast cell neoplasms are commonly diagnosed malignancies in dogs, with varying clinical presentations and outcomes. A Working Conference in 2019 proposed a classification and diagnostic criteria for these tumors, aiming to facilitate diagnostic evaluation and prognostication for better patient management.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Article
Immunology
Kun Wen, Jian-Piao Cai, Xiaodi Fan, Xiaojuan Zhang, Cuiting Luo, Kai-Ming Tang, Huiping Shuai, Lin-Lei Chen, Ricky Ruiqi Zhang, Jianwen Situ, Hoi-Wah Tsoi, Kun Wang, Jasper Fuk-Woo Chan, Shuofeng Yuan, Kwok-Yung Yuen, Hongwei Zhou, Kelvin Kai-Wang To
Summary: In this study, monoclonal antibodies (mAbs) were generated from mice immunized with spike protein trimer and receptor binding domain (RBD) of SARS-CoV-2. One mAb, WKS13, showed broad neutralizing activity against all Variants of Concern (VOCs) including the Omicron variant. These mAbs can be humanized and used as a therapeutic approach for the treatment of different variants of COVID-19.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)